News|Events|March 1, 2024

Spectral AI Appoints New CEO

Author(s)Aaron Acevedo

On February 29, Spectral AI announced that Peter M. Carlson, its current chief financial officer (CFO), will take over the role as CEO and board member of the medical diagnostics company. Carlson will succeed Wensheng Fan, who will take an advisor role after nearly four years as CEO and 14 years with the company. The move comes after the Dallas, Texas-based company made its initial public offering (IPO) on September 12, 2023, on the Nasdaq, trading under MDAI.

“We are confident he is the right person to guide Spectral AI as we evolve from a late-stage development company and commercialize our revolutionary, AI-driven wound care technology,” said Richard Cotton, chairman of the company’s board of directors.

Before joining Spectral AI, Carlson served as chief operating officer at Brighthouse Financial and chief accounting officer for MetLife. Carlson joined Spectral AI as its CFO in January of this year.

Spectral AI, which develops AI tools for medical diagnostics, received full UK Conformity Assessed (UKCA) authorization for its predictive software DeepView AI-Burn. The software helps clinicians assess a wound’s healing potential prior to medical intervention. The company also enrolled its first patient a study to validate DeepView AI for burn size and healing assessments and plans to seek FDA marketing authorization for the software in 2025. It is also investigating other clinical applications for DeepView, including its use for venous leg ulcers, critical limb ischemia, guided therapy, and more (1).

Reference

Technology. Spectral AI, Inc. 2024. https://www.spectral-ai.com/wound-healing-technologies/ (accessed 2024-3-1)


Related to this article

Human body wireframe on glowing platform undergoing futuristic body scan. © sergray(noAIelemens) -chronicles-stock.adobe.com
Jurgen Popp, Thomas Mayerhofer, and colleagues at Leibniz IPHT and Friedrich Schiller University Jena introduce the Personalized Optical Digital Twin (PODT), a Photonics21 contribution to Europe's Virtual Human Twin ecosystem that connects molecular photonics—Raman blood analysis, coherent Raman tissue imaging, and multimodal endomicroscopy—with longitudinal physiology and clinical data. Drawing on the published multicenter INTELLIGENCE trials, the authors argue that technical feasibility and clinical utility must be evaluated separately as the field moves toward Europe's FP10 research agenda.
Scientist With Portable Spectrometer in Natural Field Setting ©  By Tika -chronicles-stock.adobe.com
The bulky bench-top NIR spectrometer is quietly being dismantled and rebuilt as a wafer-scale photonic chip, a self-calibrating algorithm, and a sensor small enough to ride in a shirt pocket. What once demanded a grating, a moving mirror, and a climate-controlled lab now fits inside a handheld module, a bioreactor probe, or a drone payload, and it increasingly figures out what it is looking at on its own.
Artist’s conception of a futuristic laser-based instrument ©  MD AL AMIN-chronicles-stock.adobe.com
Raman spectroscopy is shedding its bulky, benchtop reputation as chip-scale spectrometers, tip-enhanced probes, and AI-native detectors push the technique into pockets, production lines, and single molecules. The result is an instrument category being rebuilt from the optics up, faster, smaller, deeper, and smarter than the Raman systems of even five years ago.